Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Next Previous
Trial Profile

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Sofosbuvir/velpatasvir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms C-FORWARD
  • Sponsors Atea Pharmaceuticals

Most Recent Events

  • 12 Aug 2026 According to an Atea Pharmaceuticals media release, following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.
  • 28 Jul 2026 According to an Atea Pharmaceuticals media release, topline data from the trial is expected in early 2027.
  • 25 Jun 2026 Status changed from recruiting to active, no longer recruiting. C-FORWARD enrolled more than 880 treatment-naive patients across approximately 120 clinical sites in 17 countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top